In a recent article Kirschenbaum et al., described a 50 years female with sensory ataxic neuropathy with dysarthria and ophthalmoplegia (SANDO) syndrome due to the mutation c.467A>T in the POLG1 gene [1] . SANDO, first described by Fadic et al. in 1997 [2] , is clinically characterized by the triad of sensory ataxic neuropathy, dysarthria, and ophthalmoparesis [3] . We have the following comments and concerns.
The patient died suddenly from cardiac arrest [1] . Was the individual history positive for palpitations, syncopes, or episodes of heart failure? Was the family history positive for sudden cardiac death (SCD) as has been previously reported [4] ? Did the patient undergo cardiologic work-up before decease? Was a Holter-ECG recorded or an echocardiography carried out? Did the patient undergo cardio-pulmonary resuscitation? Was there any indication on autopsy for the presence of left ventricular hypertrabeculation/noncompaction (LVHT) most frequently found in mitochondrial disorders and complicated by stroke/ embolism, heart failure, ventricular arrhythmias, or SCD [5] . Since SANDO may go along with anxiety [6] it would be interesting to know if the patient had died suddenly from the complications of Takotsubo syndrome (TTS), also known as acute stress cardiomyopathy.
The authors suspect histological and histochemical changes in the muscle [1] . Did the patient manifest with clinical features of myopathy other than ptosis or external ophthalmoplegia? Did she complain about muscle cramps, easy fatigability, or exercise intolerance? Was the muscle investigated at autopsy?
The patient was compound heterozygous for two POLG1 variants, c.1399G>A and c.2243G>C [1] as has been previously reported [6] . Were the mutations hereditary or sporadic? Were the parents or siblings investigated for the two POLG1 variants? Were any other first-degree relatives investigated neurologically or for the mutations?
Patients with SANDO typically show cerebellar atrophy, and fissures and hyperintense lesions in the olivary nuclei, cerebellar white matter, and the dorsomedial thalami [7] . Did the patient undergo a second cerebral imaging for followup and were these typical abnormalities detectable on MRI? Did any other of the mutation carriers in the family undergo cerebral imaging?
The patient received immunoglobulins [1] . Which was the rationale to apply this compound? Were there any clinical or chemical indications for the presence of an immune neuropathy? Immunoglobulins have not been reported previously to exhibit a beneficial therapeutic effect in SANDO.
SANDO may be associated with multiple deletions of the mtDNA [8, 9] . Was any tissue investigated for the presence or absence of secondary mtDNA deletions? Overall, this interesting case and the review of the literature show that SANDO is indeed a multiorgan disorder and not restricted to the cerebrum, peripheral nerves, and the extraocular muscles. Detection of an index case with SANDO requires extensive investigations of other first-degree family members.
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Manifestation

Mutated gene Reference
Central nervous system Dysarthria none [7] Dysphagia ANT1/POLG1 [4] Tremor POLG1 [10] Cognitive impairment POLG1 [10] Dementia POLG1 [10] Epilepsy none [11, 12] Olivary degeneration POLG1 [13] Parkinsonism POLG1 [14] Headache POLG1 [12] Lactate elevation ANT1/POLG1 [4, 12] Depression
Ears
Impaired hearing ANT1/POLG1 [4]
Endocrine organs Early menopause POLG1 [6] Heart Sudden cardiac death POLG1 [1] Gastrointestinal tract Constipation (MNGIE-like) POLG1 [6] Peripheral nerves Sensory ataxia POLG1 [10] Gait disturbance/falls ANT1/POLG1 [4] Sensory-motor neuropathy POLG1 [10] Muscle Ptosis POLG1 [6] Ophthalmoparesis POLG1 [10] Quadruparesis ANT1/POLG1 [4] Muscle cramps POLG1 [6] Lactic acidosis ANT1/POLG1 [4] 
